DSpace Repository

Serology testing in the COVID-19 pandemic response

Show simple item record

dc.contributor.author Peeling, R.W.
dc.contributor.author Wedderburn, C.J.
dc.contributor.author Garcia, P.J.
dc.contributor.author Boeras, D.
dc.contributor.author Fongwen, N.
dc.contributor.author Nkengasong, J.
dc.contributor.author Sall, A.
dc.contributor.author Tanuri, A.
dc.contributor.author Heymann, D.L.
dc.date.accessioned 2020-12-14T16:10:03Z
dc.date.available 2020-12-14T16:10:03Z
dc.date.issued 2020
dc.identifier.uri https://hdl.handle.net/20.500.12866/8758
dc.description.abstract The collapse of global cooperation and a failure of international solidarity have led to many low-income and middle-income countries being denied access to molecular diagnostics in the COVID-19 pandemic response. Yet the scarcity of knowledge on the dynamics of the immune response to infection has led to hesitation on recommending the use of rapid immunodiagnostic tests, even though rapid serology tests are commercially available and scalable. On the basis of our knowledge and understanding of viral infectivity and host response, we urge countries without the capacity to do molecular testing at scale to research the use of serology tests to triage symptomatic patients in community settings, to test contacts of confirmed cases, and in situational analysis and surveillance. The WHO R&D Blue Print expert group identified eight priorities for research and development, of which the highest is to mobilise research on rapid point-of-care diagnostics for use at the community level. This research should inform control programmes of the required performance and utility of rapid serology tests, which, when applied specifically for appropriate public health measures to then be put in place, can make a huge difference. en_US
dc.language.iso eng
dc.publisher Elsevier
dc.relation.ispartof urn:issn:1474-4457
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject UNAVAILABLE en_US
dc.title Serology testing in the COVID-19 pandemic response en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1016/S1473-3099(20)30517-X
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.00 es_PE


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics